TAK-931

Research use only, not for human use.

TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.

TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM; prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis, demonstrates antiproliferative activity with cancer cell lines and tumor growth inhibition (TGI) in murine ectopic xenograft models. Colon Cancer,Phase 2 Clinical.

——

——

Simurosertib | TAK931

Cell Cycle/DNA Damage

CDK

CDK

Cancer

Colon Cancer

1330782-76-7

341.433

C17H19N5OS

>98% (HPLC)

DMSO : 75 mg/mL 219.66 mM

O=C1C2=C(C=C(C3=CNN=C3C)S2)N=C([C@H]4N(CC5)CCC5C4)N1

Thieno[3,2-d]pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo[2.2.2]oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-

(-20℃)

With Ice Pack

≥ 2 years